These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17848948)

  • 1. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
    Fanciullino R; Giacometti S; Mercier C; Aubert C; Blanquicett C; Piccerelle P; Ciccolini J
    Br J Cancer; 2007 Oct; 97(7):919-26. PubMed ID: 17848948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study.
    Fanciullino R; Giacometti S; Aubert C; Fina F; Martin PM; Piccerelle P; Ciccolini J
    Pharm Res; 2005 Dec; 22(12):2051-7. PubMed ID: 16222443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
    Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer.
    Kim SL; Kim SH; Trang KT; Kim IH; Lee SO; Lee ST; Kim DG; Kang SB; Kim SW
    Cancer Lett; 2013 Jul; 335(2):479-86. PubMed ID: 23507557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
    Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
    Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
    de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
    Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.
    Zhang H; Tang J; Li C; Kong J; Wang J; Wu Y; Xu E; Lai M
    Cancer Lett; 2015 Jan; 356(2 Pt B):781-90. PubMed ID: 25449431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
    Wen C; Chen J; Zhang D; Wang H; Che J; Qin Q; He L; Cai Z; Lin M; Lou Q; Huang L; Chen D; Iwamoto A; Ren D; Wang L; Lan P; Wang J; Liu H; Yang X
    Cancer Lett; 2016 Dec; 383(2):295-308. PubMed ID: 27713084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
    Sen K; Banerjee S; Mandal M
    Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by Mycoplasma infection.
    Jetté L; Bissoon-Haqqani S; Le François B; Maroun JA; Birnboim HC
    Anticancer Res; 2008; 28(4B):2175-80. PubMed ID: 18751392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells.
    Inaba M; Naoe Y; Mitsuhashi J
    Biol Pharm Bull; 1998 Jun; 21(6):569-73. PubMed ID: 9657039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
    Subbarayan PR; Lee K; Ardalan B
    Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines.
    McGinn CJ; Pestalozzi BC; Drake JC; Glennon MC; Kunugi K; Otterson G; Allegra CJ; Johnston PG; Kinsella TJ
    Cancer J; 2000; 6(4):234-42. PubMed ID: 11038143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
    Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
    Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer.
    Fan CW; Fan HA; Hsu SH; Chan CC; Chen SY; Hsu YH; Chan EC
    Cancer Lett; 2004 Oct; 214(2):181-8. PubMed ID: 15363544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
    de la Cueva A; Ramírez de Molina A; Alvarez-Ayerza N; Ramos MA; Cebrián A; Del Pulgar TG; Lacal JC
    PLoS One; 2013; 8(6):e64961. PubMed ID: 23762272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.